GSK divested Haleon, its consumer group, in July 2022. Given the strong valuations of consumer healthcare companies, we expect this unit will yield a stronger valuation than what was implied ...

GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

Harvey Jones has spotted signs of life in the GSK share price. Which is a relief after its recent troubles, so can the FTSE ...

The U.S. Food and Drug Administration has granted approval to a new antibiotic to treat urinary tract infections in women and ...

Pete Petersen, 58, has been looking for work since last February after he was laid off from his corporate job, suspecting ...

Me filed for bankruptcy on Sunday, hit by faltering demand for its ancestry testing kits as it struggled to contain the ...

GSK's HIV business, run through joint venture company ViiV Healthcare, also had a good quarter with sales up 14% to £1.4 billion, led by gains for two-drug oral regimens Dovato (dolutegravir ...

DNA testing company 23andMe was a white-hot Silicon Valley startup for years, and Anne Wojcicki was a celebrity CEO. But ...

Me’s weekend bankruptcy filing has ignited concerns among consumers who provided the company with their genetic information ...

23andme says it owns the aggregated genetic data of its customers, meaning it can sell it to the highest bidder ...

Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth.